Keep up to date on AgNovos events and related news
11/9/2021 | News
It is with great pleasure that AgNovos Healthcare announces the recipients of this year’s ESCEO-AgNovos Young Investigator Award presented at the World Congress on Osteoporosis in August 2021.
11/4/2021 | News
AgNovos Healthcare is pleased to announce the publication of a manuscript titled “AGN1 implant material to treat bone loss: Resorbable implant forms normal bone with and without alendronate in a canine critical size humeral defect model” in the peer-reviewed journal Bone.
9/29/2021 | News
AgNovos Healthcare is pleased to announce an exclusive option agreement with Asahi Kasei Pharma Corporation.
4/19/2021 | News
AgNovos Healthcare, a developer of medical technology products leveraging regenerative medicine to treat the local effects of bone disease, announced today that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) kit has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration.
4/8/2020 | News
The recently issued press release on the FDA's "Breakthrough Designation" for AgNovos' newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has generated a strong of interest in the industry and has been posted on several reputable press portals.
3/26/2020 | News
AgNovos Healthcare is pleased to announce that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
